One-Year Outcomes of Repeat XEN Gel Stent Implantation for Prior XEN Failure: A Retrospective Study.

Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2026-09-23 eCollection Date: 2026-01-01 DOI:10.2147/OPTH.S625088
Arkadiy Yadgarov, Savannah Wegemer
{"title":"One-Year Outcomes of Repeat XEN Gel Stent Implantation for Prior XEN Failure: A Retrospective Study.","authors":"Arkadiy Yadgarov, Savannah Wegemer","doi":"10.2147/OPTH.S625088","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the 12-month outcomes of repeat XEN gel stent implantation in eyes with prior XEN failure.</p><p><strong>Patients and methods: </strong>This single-center retrospective chart review included 24 eyes of 24 patients with a previously failed XEN stent, who underwent repeat XEN gel stent implantation between April 2019 and June 2023. Outcome measures included changes in mean intraocular pressure (IOP) and number of IOP-lowering medications from baseline (prior to repeat XEN) to postoperative 12 months, assessment of surgical success defined as achieving IOP ≤18 mmHg without medications (complete success)/on the same or fewer medications (qualified success), without secondary surgical intervention (SSI), and a morphologically functional bleb.</p><p><strong>Results: </strong>The mean age of patients was 65.3 ± 10.9 years. The study population was predominantly African American (79.2%). Among the eyes not requiring SSI, there was a 43.5% reduction in mean IOP from baseline to postoperative 12 months, which was statistically significant (23.50 ± 5.58 mmHg at baseline to 13.28 ± 3.54 mmHg at 12 months (p <0.001). The postoperative 12-month complete success rate was 16.7%, and the qualified success rate was 66.7%. The mean number of IOP-lowering medications also declined significantly from 3.00 ± 1.37 to 1.28 ± 1.13 (p = 0.002), revealing a 57% reduction from baseline to 12 months. No vision-threatening complications were reported.</p><p><strong>Conclusions: </strong>Repeat XEN gel stent implantation may be a viable surgical option for prior XEN failure, providing meaningful reductions in IOP and medication burden in majority of patients. These findings support consideration of a second XEN stent before transitioning to more invasive filtering surgeries.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"20 ","pages":"625088"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617004/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S625088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To evaluate the 12-month outcomes of repeat XEN gel stent implantation in eyes with prior XEN failure.

Patients and methods: This single-center retrospective chart review included 24 eyes of 24 patients with a previously failed XEN stent, who underwent repeat XEN gel stent implantation between April 2019 and June 2023. Outcome measures included changes in mean intraocular pressure (IOP) and number of IOP-lowering medications from baseline (prior to repeat XEN) to postoperative 12 months, assessment of surgical success defined as achieving IOP ≤18 mmHg without medications (complete success)/on the same or fewer medications (qualified success), without secondary surgical intervention (SSI), and a morphologically functional bleb.

Results: The mean age of patients was 65.3 ± 10.9 years. The study population was predominantly African American (79.2%). Among the eyes not requiring SSI, there was a 43.5% reduction in mean IOP from baseline to postoperative 12 months, which was statistically significant (23.50 ± 5.58 mmHg at baseline to 13.28 ± 3.54 mmHg at 12 months (p <0.001). The postoperative 12-month complete success rate was 16.7%, and the qualified success rate was 66.7%. The mean number of IOP-lowering medications also declined significantly from 3.00 ± 1.37 to 1.28 ± 1.13 (p = 0.002), revealing a 57% reduction from baseline to 12 months. No vision-threatening complications were reported.

Conclusions: Repeat XEN gel stent implantation may be a viable surgical option for prior XEN failure, providing meaningful reductions in IOP and medication burden in majority of patients. These findings support consideration of a second XEN stent before transitioning to more invasive filtering surgeries.

一项回顾性研究:重复XEN凝胶支架植入术治疗先前XEN失败的一年结果
目的:评价既往XEN失败的眼重复XEN凝胶支架植入术12个月的疗效。患者和方法:本单中心回顾性图表回顾包括24例既往XEN支架失败的患者的24只眼睛,这些患者在2019年4月至2023年6月期间再次接受了XEN凝胶支架植入术。结果测量包括从基线(重复XEN之前)到术后12个月的平均眼压(IOP)和降眼压药物数量的变化,评估手术成功,定义为在没有药物治疗的情况下达到IOP≤18 mmHg(完全成功)/使用相同或更少的药物治疗(合格成功),没有二次手术干预(SSI),以及形态学功能的水泡。结果:患者平均年龄65.3±10.9岁。研究人群主要是非裔美国人(79.2%)。在不需要SSI的眼睛中,从基线到术后12个月平均IOP下降43.5%,具有统计学意义(基线23.50±5.58 mmHg至12个月13.28±3.54 mmHg)。结论:重复XEN凝胶支架植入术可能是先前XEN失败的一种可行的手术选择,可显著降低大多数患者的IOP和药物负担。这些发现支持在过渡到更具侵入性的过滤手术之前考虑第二次XEN支架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书